Clinical Research Directory
Browse clinical research sites, groups, and studies.
Secondary Databased Post-marketing Surveillance Study of BNT162b2
Sponsor: Pfizer
Summary
This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.
Key Details
Gender
All
Age Range
6 Months - Any
Study Type
OBSERVATIONAL
Enrollment
14302529
Start Date
2025-04-23
Completion Date
2025-05-28
Last Updated
2026-07-10
Healthy Volunteers
No
Conditions
Interventions
Tozinameran (BNT162b2)
1. 12 years or older * Primary series: 2 doses, 30 μg each, administered 21 days apart * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot 2. 5 to 11 years of age * Primary series: 2 doses, 10 μg each, administered 21 days apart * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot 3. 6 months to 4 years of age * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)
Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)
1\. 12 years or older \- Single booster dose, 15/15 μg, administered after ≥3 months after primary series
Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
1\. 12 years or older \- Single booster dose, 15/15 μg administered after ≥3 months after primary series
Locations (1)
Pfizer
Seoul, South Korea